Fiore Cannabis Ltd. (FIORF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.83: the stock has moved about 17% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerFiore Cannabis Ltd. (FIORF) trades at $0.00001. Fiore Cannabis Ltd. cultivates, produces, and distributes medical and recreational marijuana in the United States. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for FIORF: FIORF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Fiore Cannabis Ltd. (FIORF) Healthcare & Pipeline Overview
Fiore Cannabis Ltd. operates in the U.S. cannabis market, focusing on cultivation, production, and distribution of medical and recreational marijuana. The company also runs a dispensary in California, integrating both upstream and downstream operations within a competitive and evolving regulatory landscape.
What Is the Investment Thesis for FIORF?
Fiore Cannabis Ltd. presents a speculative investment opportunity within the evolving U.S. cannabis market. The company's vertical integration, encompassing cultivation, production, and retail through its California dispensary, offers potential for margin capture across the value chain. However, the company's negative profit margin of -280.9% indicates significant operational challenges. Key catalysts include potential regulatory changes in the U.S. that could expand market access. Investors should closely monitor the company's ability to improve profitability and manage its operations effectively. The company's beta of 0.83 suggests lower volatility compared to the overall market. The absence of a dividend reflects its focus on reinvesting earnings for growth. The market capitalization of $0.00B indicates that it is a micro-cap stock.
Based on FMP financials and quantitative analysis
FIORF Key Highlights
Operates in the U.S. medical and recreational cannabis market.
- Vertically integrated with cultivation, production, and retail operations.
- Gross margin of 22.6% indicates potential for profitability improvements.
- Negative profit margin of -280.9% reflects current operational challenges.
- Beta of 0.83 suggests lower volatility compared to the market.
Who Are FIORF's Competitors?
FIORF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AKAN Akanda Corp. | $1.98 | -10.41% | — | |
| SNOA Sonoma Pharmaceuticals, Inc. | $1.24 | -0.80% | $5.94M | — |
| APUS Apimeds Pharmaceuticals US, Inc. | $5.03 | +56.21% | $7.59M | — |
| BFRI Biofrontera Inc. | $1.01 | -2.40% | $13.0M | — |
| COSM COSM | $0.38 | -1.58% | $20.7M | — |
| QNTM Quantum BioPharma Ltd. | $3.44 | +0.44% | $22.0M | — |
| AYTU Aytu BioPharma, Inc. | $2.07 | -0.96% | $22.2M | — |
| TXMD TherapeuticsMD, Inc. | $2.05 | +0.99% | $23.7M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are FIORF's Key Strengths?
Vertically integrated operations.
- Dispensary in California.
- Focus on both medical and recreational markets.
What Are FIORF's Weaknesses?
Negative profit margin.
- Limited geographic presence.
- Small market capitalization.
What Are the Key Risks for FIORF?
Financial-distress signal — its Altman Z-Score of -11.63 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Intense competition in the cannabis industry could pressure margins and limit market share.
- Fluctuations in cannabis prices could impact revenue and profitability.
- Changes in state and local regulations could create compliance challenges and increase costs.
- Limited access to capital could constrain growth opportunities.
- Negative profit margin indicates operational inefficiencies.
What Are FIORF's Competitive Advantages?
- Vertical integration provides control over the supply chain.
- Dispensary operations provide direct access to consumers.
- Brand recognition in the California market.
What Does FIORF Do?
Fiore Cannabis Ltd., formerly known as Citation Growth Corp., rebranded in October 2020 to reflect its focus on the cannabis industry. Incorporated in 2007 and headquartered in Kelowna, Canada, the company cultivates, produces, and distributes medical and recreational marijuana in the United States. Fiore Cannabis operates a dispensary in California, allowing it to directly serve consumers. The company's operations span the entire value chain, from cultivation to retail, positioning it as a vertically integrated player in the cannabis market. Fiore Cannabis aims to capitalize on the growing demand for cannabis products in the U.S., navigating the complex regulatory environment to establish a strong market presence. The company's strategy involves optimizing its cultivation and production processes to ensure high-quality products and efficient operations. By focusing on both medical and recreational markets, Fiore Cannabis seeks to diversify its revenue streams and cater to a broad customer base.
What Products and Services Does FIORF Offer?
- Cultivates medical marijuana.
- Cultivates recreational marijuana.
- Produces medical marijuana products.
- Produces recreational marijuana products.
- Distributes medical marijuana products.
- Distributes recreational marijuana products.
- Operates a dispensary in California.
How Does FIORF Make Money?
- Cultivation and production of cannabis.
- Distribution of cannabis products to dispensaries.
- Retail sales through its own dispensary.
What Industry Does FIORF Operate In?
Fiore Cannabis Ltd. operates within the rapidly expanding U.S. cannabis industry. The market is characterized by increasing legalization, evolving regulations, and growing consumer demand for both medical and recreational cannabis products. The industry is highly competitive, with numerous players vying for market share. Key trends include the consolidation of smaller companies, the development of new cannabis-infused products, and the increasing focus on quality and branding. Fiore Cannabis competes with other cannabis producers and retailers, including CBGI, HCANF, LOWLF, MDIT, and MDXL, all of whom are navigating similar regulatory and market dynamics.
Who Are FIORF's Key Customers?
- Medical marijuana patients in the U.S.
- Recreational cannabis users in the U.S.
- Dispensaries in California.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Fiore Cannabis Ltd. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Kelowna, CA. The company is led by CEO Erik Anderson. FIORF has traded publicly since 2015.
Key Financial Metrics
Return on assets is -50.7%, showing how much profit it generates from its asset base. A current ratio of 0.25 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Fiore Cannabis Ltd.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -11.63 places it in the distress zone, a signal of elevated financial risk.
FIORF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
FIORF Latest News
No recent news available for FIORF.
FIORF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for FIORF.
Price Targets
Wall Street price target analysis for FIORF.
FIORF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for FIORF; grades run from A+ (80-100) to F (below 30).
Leadership: Erik Anderson
CEO
Erik Anderson serves as the CEO of Fiore Cannabis Ltd. His background includes experience in the cannabis industry, with a focus on operations and business development. He has been involved in various aspects of the cannabis value chain, from cultivation to retail. Anderson's expertise lies in navigating the complex regulatory landscape and building sustainable business models in the cannabis sector. He is committed to driving growth and innovation at Fiore Cannabis.
Track Record: Under Erik Anderson's leadership, Fiore Cannabis Ltd. has focused on expanding its operations in the U.S. cannabis market. Key milestones include the rebranding of the company and the optimization of its cultivation and production processes. Anderson has also overseen the development of new cannabis products and the enhancement of the company's retail operations. His strategic decisions have aimed at improving the company's profitability and competitiveness.
FIORF OTC Market Information
The OTC Other tier, also known as the Pink Sheets, represents the lowest tier of the over-the-counter (OTC) market. Companies listed on this tier typically do not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB, or major exchanges like NYSE or NASDAQ. This tier is often populated by speculative or distressed companies, and may include companies with limited operating history or those that are thinly traded. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Lack of regulatory oversight.
- Speculative nature of the business.
- Verify the company's legal standing and registration.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive position.
- Evaluate the management team's experience and track record.
- Understand the regulatory environment and potential risks.
- Monitor trading volume and price volatility.
- Consult with a financial advisor.
- Operation of a dispensary in California.
- Focus on both medical and recreational markets.
- Rebranding efforts to focus on the cannabis industry.
FIORF Healthcare Stock FAQ
What do analysts say about FIORF stock?
As of 2026-03-17, there is no readily available analyst coverage for FIORF stock due to its OTC listing and small market capitalization. Investors should conduct their own thorough research and due diligence before investing in FIORF. Key valuation metrics, such as price-to-earnings ratio, are not meaningful due to the company's negative earnings.
What are the main risks for FIORF?
The main risks for Fiore Cannabis Ltd. include intense competition in the cannabis industry, which could pressure margins and limit market share. Changes in state and local regulations could create compliance challenges and increase costs.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Financial data is limited due to the company's OTC listing.
- Analyst coverage is unavailable.
- The cannabis industry is subject to rapid regulatory changes.